BR112020019094A2 - Composições e métodos para tratar prurido - Google Patents

Composições e métodos para tratar prurido Download PDF

Info

Publication number
BR112020019094A2
BR112020019094A2 BR112020019094-2A BR112020019094A BR112020019094A2 BR 112020019094 A2 BR112020019094 A2 BR 112020019094A2 BR 112020019094 A BR112020019094 A BR 112020019094A BR 112020019094 A2 BR112020019094 A2 BR 112020019094A2
Authority
BR
Brazil
Prior art keywords
percent
fact
pharmaceutical composition
eds
composition according
Prior art date
Application number
BR112020019094-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Wendy Huang Chern
Chan-Jung LI
Shu-Wen Kuo
David Chih-Kuang CHOU
Yu-En TIEN
Original Assignee
Shanghai Lumosa Therapeutics Co., Ltd
Lumosa Therapeutics Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Lumosa Therapeutics Co., Ltd, Lumosa Therapeutics Co., Ltd. filed Critical Shanghai Lumosa Therapeutics Co., Ltd
Publication of BR112020019094A2 publication Critical patent/BR112020019094A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112020019094-2A 2018-03-29 2019-03-28 Composições e métodos para tratar prurido BR112020019094A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650108P 2018-03-29 2018-03-29
US62/650,108 2018-03-29
PCT/US2019/024706 WO2019191511A1 (en) 2018-03-29 2019-03-28 Compositions and methods for treating pruritus

Publications (1)

Publication Number Publication Date
BR112020019094A2 true BR112020019094A2 (pt) 2020-12-29

Family

ID=68054657

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020019094-2A BR112020019094A2 (pt) 2018-03-29 2019-03-28 Composições e métodos para tratar prurido

Country Status (13)

Country Link
US (2) US20190298702A1 (cg-RX-API-DMAC7.html)
EP (1) EP3755328A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021525225A (cg-RX-API-DMAC7.html)
KR (1) KR20200138730A (cg-RX-API-DMAC7.html)
CN (1) CN112040948A (cg-RX-API-DMAC7.html)
AU (1) AU2019243571A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020019094A2 (cg-RX-API-DMAC7.html)
CA (1) CA3094710A1 (cg-RX-API-DMAC7.html)
IL (1) IL277463A (cg-RX-API-DMAC7.html)
MX (1) MX2020009813A (cg-RX-API-DMAC7.html)
RU (1) RU2020130919A (cg-RX-API-DMAC7.html)
TW (1) TWI729371B (cg-RX-API-DMAC7.html)
WO (1) WO2019191511A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121401263A (zh) * 2020-02-14 2026-01-27 帝国制药美国公司 外用纳洛酮组合物及其使用方法
CN113797167B (zh) * 2020-06-16 2024-05-10 苏州恩华生物医药科技有限公司 一种塞纳布啡的储库制剂
IL298929A (en) * 2020-06-30 2023-02-01 Dermira Inc IRAK4 inhibitors and their topical uses
WO2022175973A1 (en) * 2021-02-18 2022-08-25 Navin Saxena Research And Technology Private Limited An injectable composition for long term delivery of nalbuphine or nalbuphine ester prodrug or its salts and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130759C (cg-RX-API-DMAC7.html) * 1965-10-07
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
US6503944B1 (en) * 1999-05-26 2003-01-07 The Andrew Jergens Company Anhydrous skin care composition
US6967023B1 (en) * 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
ES2188481T3 (es) * 2000-04-27 2003-07-01 Oliver Yoa-Pu Hu Derivados de polinalbufina.
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US20070093517A1 (en) * 2005-10-24 2007-04-26 Gary Newton Local anesthetic compositions
RU2596488C2 (ru) * 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
JP6247223B2 (ja) * 2011-12-08 2017-12-13 ライジェル ファーマシューティカルズ, インコーポレイテッド 化合物を投与するための局所用製剤
US20140112957A1 (en) * 2012-10-19 2014-04-24 Oliver Yao-Pu Hu Analegisic (Sebacoyl dinalbuphine ester) PLGA controlled release formulation form
WO2015192071A1 (en) * 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus
JP6935393B2 (ja) * 2015-05-28 2021-09-15 ルモサ セラピューティクス カンパニー, リミテッド セバコイルジナルブフィンエステルの徐放のための医薬製剤

Also Published As

Publication number Publication date
AU2019243571A1 (en) 2020-10-15
EP3755328A4 (en) 2021-11-10
EP3755328A1 (en) 2020-12-30
TW202002977A (zh) 2020-01-16
RU2020130919A3 (cg-RX-API-DMAC7.html) 2022-04-29
CN112040948A (zh) 2020-12-04
CA3094710A1 (en) 2019-10-03
TWI729371B (zh) 2021-06-01
US20190298702A1 (en) 2019-10-03
RU2020130919A (ru) 2022-04-29
KR20200138730A (ko) 2020-12-10
MX2020009813A (es) 2020-11-11
JP2021525225A (ja) 2021-09-24
WO2019191511A1 (en) 2019-10-03
US20220362226A1 (en) 2022-11-17
IL277463A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
US20220362226A1 (en) Compositions and methods for treating pruritus
US11517546B2 (en) High concentration local anesthetic formulations
US20130116271A1 (en) Tacrolimus-containing oil-in-water type creamy composition
KR20100075476A (ko) 항진균 조성물
KR20230004644A (ko) 약제학적 조성물
KR20230122024A (ko) 타피나로프의 겔, 연고, 및 폼 제형 및 사용 방법
WO2016198469A1 (en) Penetration of alpha-hydroxy acids from water-free emulsions
WO2015108045A1 (ja) 経皮投与用外用剤
AU2022202941A1 (en) Stable topical compositions of fenoldopam
US10441530B2 (en) Skin penetration enhancing systems for polar drugs
CA2704859A1 (en) Topical treatment with dapsone in g6pd-deficient patients
JP5897299B2 (ja) ローション剤
US20090176749A1 (en) Oil-in-water emulsion lotion containing 22-oxa-1alpha, 25-dihydroxyvitamin d3 and method of treatment of skin disorder using the same
HK40036943A (en) Compositions and methods for treating pruritus
JPWO2016194942A1 (ja) 経皮投与用外用剤
US20260130905A1 (en) Topical formulations of deucravacitinib
WO2021102072A1 (en) Composition and method for skin treatment
BR112018069741B1 (pt) Composição para aplicação tópica, método para fabricar uma composição para aplicação tópica, e, uso de uma composição

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]